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Summary Maternal factors including atopy and smoking during pregnancy are
associated with asthma risk during childhood. Suggested mechanisms include
transmission of specific maternal alleles and maternal influences on the intrauterine
environment. We have previously shown that polymorphism in glutathione S-
transferase, GSTP1 is associated with airway hyperresponsiveness (AHR) and atopy
in adults. We now hypothesise that GSTP1 genotypes in the mother and child, but not
the father, mediate asthma phenotypes in the child. One hundred and forty-five
Caucasian families were recruited via an asthmatic proband aged 7–18 years. Atopy
and asthma were assessed using a questionnaire, skin prick testing, serum IgE,
spirometry and methacholine challenge (PC20, dose–response slopeFDRS). GSTP1
genotyping was determined using PCR. GSTP1 Val105/Val105 genotype in the child was
associated with a reduced risk of atopy ðP ¼ 0:038Þ and AHR (PC20, P ¼ 0:046; DRS,
P ¼ 0:032). In mothers ðP ¼ 0:014Þ but not fathers ðP ¼ 0:623Þ; Val105/Val105 was
associated with a reduced risk of AHR in the child. We have identified, for the first
time, an association between maternal genotype and the child’s asthma phenotype
that appears not to be due to transmission of specific maternal alleles. This
preliminary data supports the view of in utero effects of maternal genotype and adds
new insights into the possible mechanisms by which maternal factors may influence
development of childhood asthma.
& 2003 Elsevier Ltd. All rights reserved.
Introduction
During gestation, mother and foetus may be
exposed to agents that can adversely affect foetal
development. For example, maternal smoking
during pregnancy is associated with impaired foetal
airway growth and an increased risk of asthma
and wheezing in later life.1 It is likely therefore,
that the effectiveness of maternal systems that
detoxify potentially harmful chemicals will signifi-
cantly influence proper foetal development. The
detoxication of many drugs and environmental
electrophiles is catalysed by enzymes that are
encoded by polymorphic genes such as those that
comprise the glutathione S-transferase (GST)
supergene family.2
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Maternal alleles may influence foetal well-being
if they influence the catalytic effectiveness of
detoxifying enzymes encoded by maternal genes or,
if high risk alleles are transmitted to affected
offspring with greater frequency than would be
expected by Mendelian inheritance.3 The latter
appears to result from the selective inactivation of
genetic material from one parent in all but the
germ cells of the foetus (genetic imprinting). Thus,
in the context of atopy, children of atopic mothers
are more likely to develop the trait than those with
atopic fathers and, atopy is more common in the
mothers than the fathers of children with asth-
ma.4,5 Cookson et al.6 first showed that in sibling
pairs, atopy was linked to transmission of alleles
from maternal but not paternal, 11q13 chromo-
somes.
Inherited differences in paternal genes may also
potentially influence the effect of maternal ex-
posure on foetal development. Genes expressed in
the placenta are paternal in origin.7 Thus, their
enzyme products may provide further defence
against foetal exposure to exogenous toxins.
The finding that alleles located on chromosome
11q13 are associated with risk of atopy in the child
is important as this chromosomal region is a hotspot
for asthma-related genes. Although the high affi-
nity IgE receptor is accepted by many as being
important in atopy, the associations with other
asthma phenotypes are less well-defined and it has
been suggested that many candidates are too
distant to account for the strength of the identified
associations to this region from whole genome
screens.8,9 We recently showed, in two indepen-
dent studies in adults, that polymorphism in GSTP1,
a gene located on chromosome 11q13, is associated
with risk of airway hyperresponsiveness (AHR) and
atopy.10,11 GSTP1 is strongly expressed in human
foetal lung during gestation and its expression can
be regulated by methylation, a key mechanism in
the selective allele inactivation seen in genetic
imprinting.2,12 Its enzyme product, GSTP1-1, cata-
lyses the detoxification of many environmental
toxins and by-products of oxidative stress.2
GSTP1 is polymorphic with allelic variants de-
monstrating different catalytic efficiencies due to
changes in the active site.13,14 In addition to the
wild-type, GSTP1*A allele, GSTP1*B; GSTP1*C and
GSTP1*D have been identified. GSTP1*B contains
an A-G transition, resulting in an Ile105–Val105
(I105V) change while GSTP1*D contains a C–T
transition giving rise to an Ala114–Val114 (A114V)
substitution. GSTP1*C contains both these transi-
tions. Enzymes with the valine at amino acid 105
have a seven-fold higher catalytic efficiency for
diol epoxides of polycyclic aromatic hydrocarbons
(PAH), than the isoenzymes with the isoleucine at
this position. In contrast, the Val105 enzyme is
three-fold less effective using 1-chloro-2,4-dinitro-
benzene as substrate.15,16 There is no evidence to
date of a functional effect of the A114V substitu-
tion alone (GSTP1*D), although it is suggested that
it augments the increased PAH activity of the I105V
substitution (GSTP1*C).
16 However, we were un-
able to identify any additional effect from the
A114V substitution in previous studies on asthma
phenotypes in adults and accordingly, focus only on
the I105V substitution.17
Although genetic studies have examined the
transmission of atopy-associated alleles from
mother to child, there is little data on the effect
of maternal genetic factors on development of
other asthma phenotypes such as AHR. The finding
that GSTP1 is associated with AHR and atopy in
adult asthmatics, its location on chromosome
11q13 and its utilisation of endogenous and
exogenous chemicals as substrates prompts the
suggestion that risk of asthma phenotypes in
children is determined by an interaction between
parental and foetal GSTP1 genotypes. Thus, allelic
variants in this gene could directly influence the
intrauterine environment by the catalytic effec-
tiveness of maternal, paternal and/or foetal
genotypes. While there are data linking maternal
factors to chromosome 11q13, these have concen-
trated on transmission of maternal alleles to the
child, rather than the effect of maternal genotype.
Further, while maternal factors are known to be
important in utero, the influence of maternal
genetic polymorphisms on development of asthma
phenotypes in the child is unknown. The aims of
this study are to: (i) determine whether GSTP1
genotypes are associated with risk of the asthma
associated phenotypes, atopy and AHR in children,
(ii) establish whether maternal and/or paternal
genotype affects this risk to a greater extent than
expected by Mendelian inheritance, and (iii)
determine whether the mechanism for the associa-
tion reflects transmission of specific parental
alleles to the child or provides evidence for a
direct effect of maternal genotype on the intrau-
terine environment.
Methods
Patients
One hundred and forty-five unrelated nuclear
families were recruited via an asthmatic proband
aged 7–18 years. The recruitment strategy has been
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described previously.18 All families comprised
Northern European Caucasians of British origin
(English, Scottish or Welsh) for at least 3 genera-
tions and resident in North Staffordshire. All
probands had doctor diagnosed asthma and a
history of wheeze for at least 12 months. The
presence of asthma in parents (32% of mothers, 26%
of fathers) was also based on a doctor diagnosis.
Subjects with cardiac, other respiratory or inflam-
matory diseases were excluded. Whilst we at-
tempted to recruit mother, father and proband
from each family (435 individuals), 4 fathers
refused to participate resulting in a study group
of 431 subjects (Table 1). The study was approved
by the local research ethics committee and written
informed consent was obtained from all partici-
pants.
All subjects completed a standardised observer-
administered ISAAC questionnaire,19 modified by
additional questions about asthma treatment,
hospital admissions and viral illnesses. Responses
were used to stratify subjects into 1 of 6 predefined
categories; non-asthmatic, viral-induced wheeze,
asthma (mild, moderate, severe, unclassified). All
probands were asthmatic and none had viral-
induced wheeze.
Baseline spirometry20 and methacholine chal-
lenge testing (tidal breathing method)21 were
performed in all probands. The response to
methacholine was expressed as a PC20 and a
dose–response slope (DRS).22 PC20 and DRS results
were corrected for the child’s age, gender, height,
atopic status and baseline FEV1, FVC, FEV1/FVC and
FEF25–75 (see Statistical analysis). A corrected
PC20o8mg/ml was used to define AHR. Where
methacholine challenge was contraindicated
(FEV1o 70%) probands underwent bronchodilator
challenge.20
Skin prick testing (SPT) and measurement of total
serum IgE (Immulite assay, Euro/DPC Ltd, Gwy-
nedd, Wales UK) were performed on all subjects.
Atopy was defined as a positive response to SPT
(X1 whealX3mm greater than saline in response
to a panel of 7 aeroallergens) or a total serum
IgEX100 IU/ml.
GSTP1 genotyping
Genotyping was performed by staff unaware of the
clinical status of the subjects. GSTP1 genotypes
were determined using primers to exon 5 to
identify the Ile105Val substitution.10,11 Fifteen
percent of samples were re-assayed to confirm
genotype assignments.
Statistical analysis
Chi-squared tests were used to assess associations
between GSTP1 genotype and AHR, atopy, SPT
positivity and IgEX100 IU/ml. Val105/Val105 geno-
type frequency was compared with the combined
frequencies of Ile105/Val105 and Ile105/Ile105
throughout. In probands, PC20 values were divided
into 4 categories, 0–3.9, 4–7.9, 8–15.9 and
X16mg/ml as described previously.10 These cate-
gories were selected as they best reflect the
thresholds used to define AHR in the literature.
Correction of PC20 category and DRS for
baseline parameters was then performed using
discriminant and linear regression analyses,
respectively.23–25 Linear regression of DRS against
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Table 1 Demographics of study population.
Probands Mothers Fathers
Number 145 145 141
Mean (SD) age (yr) 11.8 (2.7) 39.5 (5.5) 42.4 (6.6)
Male gender (%) 90 (62.1%) –– ––
Atopic 117 (81%) 75 (52%) 86 (61%)
SPT positive 105 (72%) 65 (45%) 75 (53%)
IgEX100 IU/mln 97 (67%) 38 (26%) 52 (37%)
Asthmatic 145 (100%) 40 (32%) 33 (26%)
FEV1 base
w 97 (19)% 100 (18)% 102 (19)%
AHR positive 91 (63%)z 43 (53%)z 30 (39%)z
Smoking during pregnancy (ever) –– 15/134 (11.2%) ––
Smoking history (ever) 2 (1.4%) 55 (37.9%) 74 (72.5%)
Smoking history (mean pack years in smokers7SD) 1.972.5 10.078.4 15.2712.3
nOne proband and one father refused IgE testing.
wFEV1¼baseline % predicted FEV1 (mean(SD)) based on European standards.
23
zCorrected AHR (AHRc); uncorrected AHR positivity: 86.8% in probands.
zBased on 81 mothers and 76 fathers who completed AHR testing.
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baseline parameters generated the equation:
corrected ln(DRSþ 2)¼ (atopy 0.686)þ (height
0.029) (gender  0.189) age  0.067)þ (FEV1/
FVC  0.043) þ (FVC 1.630)(FEV1 1.972)
(FEF2575 0.512)2.946. Associations of GSTP1
genotype with continuous variables (IgE, corrected
DRS) were assessed using the Mann–Whitney U-test.
Multivariate logistic regression was used to explore
the relationships between parent and child geno-
types, parental transmission and confounding fac-
tors such as maternal smoking. Transmission
disequilibrium testing (TDT) was performed as
described by Sham.26 All statistical analyses were
performed using the NCSS version 5 (Discriminant
analysis; Number Cruncher Statistical Systems,
Kaysville, UT) or Stata version 7: (All other
analyses; Stata Corporation, College Station, TX)
statistical packages.
Results
Table 1 shows the characteristics of the 431
individuals. DNA from two subjects (one mother,
one father) failed to amplify. Atopic status was
determined in 429/431 individuals and AHR status
in 144/145 probands. AHR status was obtained by
bronchodilator challenge in 13 and by methacholine
challenge in 122 probands. Four probands discon-
tinued methacholine challenge prior to a set end
point. Of these, 3 showed a convincing response to
bronchodilator (415% increase in FEV1). It was
therefore possible to obtain DRS values on 126
probands. A further 9 probands showed a420% fall
in FEV1 following the inhalation of saline. All 13 on
whom AHR status was obtained by bronchodilator
challenge had current asthma and were defined as
AHR positive. It was possible to obtain a corrected
DRS and PC20 category for all probands.
Associations between GSTP1 genotype
and AHR and atopy in probands
GSTP1 genotype frequencies in parents and pro-
bands were similar to those previously reported in
control subjects from North Staffordshire10 and
achieved Hardy–Weinburg equilibrium (Table 2
and 3). In probands, GSTP1 genotype was asso-
ciated with corrected AHR (AHRc) status, with
ARTICLE IN PRESS
Table 2 Relationship between GSTP1 genotype, atopy, AHR and asthma in probands.
GSTP1 genotype Odds ration P-valuen
Ile105/Ile105 Ile105/Val105 Val105/Val105 (95% CI)n
Probands 70 (48.3%) 56 (38.6%) 19 (13.1%)
ðn ¼ 145Þ
AHR ‘uncorrected’
No AHR 11 (57.9%) 5 (26.3%) 3 (15.8%)
AHR 59 (47.2%) 50 (40.0%) 16 (12.8%) 0.78 (0.22–2.77) 0.720
AHR ‘corrected’w
No AHRc 27 (50.0%) 16 (29.6%) 11 (20.4%)
AHRc 43 (47.2%) 40 (44.0%) 8 (8.8%) 0.38 (0.14–0.98) 0.046
SPT positive
Non-atopic 20 (50.0%) 12 (30.0%) 8 (20.0%)
Atopic 50 (47.6%) 44 (41.9%) 11 (10.5%) 0.47 (0.18–1.23) 0.129
IgEX100 IU/ml
Non-atopic 22 (46.8%) 16 (34.0%) 9 (19.2%)
Atopic 47 (48.5%) 40 (41.2%) 10 (10.3%) 0.49 (0.19–1.26) 0.142
Atopy
Non-atopic 13 (46.4%) 8 (28.6%) 7 (25.0%)
Atopic 57 (48.7%) 48 (41.0%) 12 (10.3%) 0.34 (0.12–0.94) 0.038
nAll odds ratios and P-values are based on comparisons of Val/Val with Ile/Val and Ile/Ile genotype (Ile/Val and Ile/Ile as the
reference category). 95% CI¼ 95% confidence intervals.
wCorrected AHR data using PC20 of 8mg/ml.
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Val105/Val105 demonstrating a protective effect
(Table 2). Analysis based on factorisation of all
three genotypes in logistic regression models
showed that, with Ile105\Ile105 as reference, Ile105\-
Val105 and Val105\Val105 genotypes gave odds ratios
of 1.57 and 0.46 (P ¼ 0:241; 0.136) respectively.
Consequently, we then compared Val105\Val105 using
Ile105/Val105 and Ile105/Ile105 combined as the
reference category. This showed that Val105/Val105
was significantly associated with reduced risk of
AHRc (Table 2). This association was also found
when analysis was restricted to atopy positive
probands (P ¼ 0:077; odds ratio 0.35, 95% CI 0.09–
1.43) although the numbers of subjects was
reduced ðn ¼ 117Þ: There was insufficient data to
examine the association in atopy negative pro-
bands. Val105/Val105 was also associated with a
significantly lower mean DRS (mean corrected DRS:
Val105/Val105 vs. Ile105/Ile105 or Ile105/Val105, 20.1
vs. 32.7, P ¼ 0:032). GSTP1 Val105/Val105 was
associated with a three-fold reduction in the risk
of atopy when IgE and SPT data were combined.
Although Val105/Val105 was not significantly asso-
ciated with a reduced risk of either SPT positivity or
total serum IgEX100 IU/ml when these were
considered individually (Table 2), odds ratios were
similar to that of the combined atopy variable.
Using TDT analysis, no significant associations were
identified between transmitted GSTP1 alleles and
AHRc ðP ¼ 0:286Þ and atopy ðP ¼ 0:756Þ:
Relationship between parental GSTP1
genotype and AHR and atopy in the child
Maternal (but not paternal) GSTP1 genotype was
significantly associated with both AHRc and atopy in
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Table 3 Association of parental GSTP1 genotype with AHRc and atopy in the child.
Maternal GSTP1 genotype Odds ratio Sig.n
Ile105/Ile105 Ile105/Val105 Val105/Val105 (95% CI)n
Child phenotype
AHRc
No AHRc 20 (37.0%) 24 (44.4%) 10 (18.5%)
AHRc 46 (51.1%) 39 (43.3%) 5 (5.6%) 0.26 (0.09–0.77) P ¼ 0:014
SPT positive
Non-atopic 16 (40.0%) 17 (42.5%) 7 (17.5%)
Atopic 50 (48.1%) 46 (44.2%) 8 (7.7%) 0.39 (0.14–1.13) P ¼ 0:084
IgEX100 IU/ml
Non-atopic 16 (34.0%) 25 (53.2%) 6 (12.8%)
Atopic 49 (51.0%) 38 (39.6%) 9 (9.4%) 0.71 (0.24–2.04) P ¼ 0:534
Atopic status
Non-atopic 10 (35.7%) 12 (42.9%) 6 (21.4%)
Atopic 56 (48.3%) 51 (44.0%) 9 (7.8%) 0.31 (0.10–0.92) P ¼ 0:034
Paternal GSTP1 genotype Odds ratio Sig.n
Ile105/Ile105 Ile105/Val105 Val105/Val105 (95% CI)n
AHRc
No-AHRc 24 (45.3%) 22 (41.5%) 7 (13.2%)
AHRc 40 (46.5%) 37 (43.0%) 9 (10.5%) 0.77 (0.28–2.13) P ¼ 0:623
SPT positive
Non-atopic 18 (46.2%) 14 (35.9%) 7 (18.0%)
Atopic 46 (46.0%) 45 (45.0%) 9 (9.0%) 0.45 (0.16–1.27) P ¼ 0:138
IgEX100 IU/ml
Non-atopic 18 (40.0%) 21 (46.7%) 6 (13.3%)
Atopic 45 (48.4%) 38 (48.9%) 10 (10.8%) 0.78 (0.27–2.23) P ¼ 0:657
Atopic status
Non-atopic 10 (37.0%) 13 (48.2%) 4 (14.8%)
Atopic 54 (48.2%) 46 (41.1%) 12 (10.7%) 0.69 (0.21–2.21) P ¼ 0:549
AHRc¼ corrected AHR status in child, SPT¼skin prick testing, 95% CI¼ 95% confidence interval. All data are based on 139
father–child and 144 mother–child pairs. One child did not complete IgE testing.
nAll odds ratios and P-values are based on comparisons of Val/Val with Ile/Val and Ile/Ile genotype (Ile/Val and Ile/Ile as the
reference category).
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the child. Analysis of factorisation genotypes using
logistic regression showed that, with Ile105\Ile105 as
reference, Ile105\Val105 and Val105\Val105 maternal
genotypes gave odds ratios of 0.71 and 0.22
(P ¼ 0:352; 0.012), respectively. Combining with
Ile105/Ile105 and Ile105/Val105 as reference category,
maternal Val105/Val105 genotype was associated
with a three- and five-fold reduction in the child’s
risk of AHRc and atopy, respectively (Table 3). The
association with AHRc was also found when analysis
was restricted to atopy positive probands
(P ¼ 0:061; odds ratio 0.28, 95% CI 0.05–1.44)
although the numbers of subjects was reduced
ðn ¼ 116Þ: There was insufficient data to examine
this association in atopy negative probands. Sig-
nificant associations were not observed for paternal
genotype, although the odds ratios for maternal
and paternal genotype and SPT positivity were
similar (Table 3).
The effect of maternal and paternal
transmission of GSTP1 Val105 alleles to
the child
Assuming the transmission of a single GSTP1 allele
from each parent, it was possible to determine
which GSTP1 allele in the child came from which
parent (parental transmission) in 136/145 pro-
bands. The remaining 8 families were triple
heterozygotes (each of the child, mother and
father were Ile105/Val105 heterozygotes) and it
was therefore not possible to determine parental
transmission. No significant associations were seen
between maternal or paternal transmission
of Val105 alleles and atopy or AHRc in the child
(Table 4).
Assessment of the inter-relationship
between GSTP1 genotype and
transmitted alleles
To assess the relative contribution to risk from
parental and child genotypes and transmitted
alleles, multivariate logistic regression was used
(Table 5). This showed that only child and maternal
genotype achieved or approached significance for
AHRc in the child. Similar, but non-significant
results were observed with SPT, IgE and overall
atopic status (Table 5). This suggests that the
genotype of both the mother and the child have a
significant independent effect on the child’s AHRc
and atopic status. There was no evidence of a
significant independent association with allele
transmission. Using a TDT approach, no significant
differences between the proportion of transmitted
and non-transmitted Val105 alleles from mothers
and fathers were identified using either AHRc
ðP ¼ 0:978Þ or atopy ðP ¼ 0:655Þ as endpoints.
The interaction between maternal and child
genotypes was further explored by comparing pairs
of subjects in which both mother and child had the
Val105/Val105 genotype. This showed that combined
Val105/Val105 genotypes conferred a significantly
reduced risk of atopy and AHRc in the child (odds
ratio (95% CI), atopy¼ 0.16(0.04–0.66), P ¼ 0:011;
AHRc¼ (0.15(0.03–0.76), P ¼ 0:022). Similar non-
significant associations were seen for SPT positivity
(odds ratio (95% CI), 0.28(0.07–1.10), P ¼ 0:070).
There was, however, no evidence of synergy
between maternal and child Val105/Val105 genotype
as the significance of the combined genotype was
lost when the individual factors (maternal and child
Val105/Val105 genotypes) were added to the model
(i.e. the regression model contained three vari-
ables; presence of both maternal and child Val105/
Val105 genotypes, presence of maternal Val105/
Val105 genotypes alone and, presence of child
Val105/Val105 genotypes alone).
Correction for maternal smoking and
atopic status
Independent associations between maternal and
child genotype and the child’s AHRc remained
significant after correction for maternal smoking
during pregnancy and maternal and paternal atopic
status (maternal Val105/Val105: P ¼ 0:010; odds ratio
0.19; child Val105/Val105: P ¼ 0:014; odds ratio
0.23). Associations with atopy in the child were
also unchanged by this correction (maternal Val105/
Val105: P ¼ 0:046; odds ratio 0.30; child Val105/
Val105: P ¼ 0:013; odds ratio 0.23). Although the
trend was maintained, the significance of the
association between maternal genotype and AHRc
in the child was reduced after correction for the
child’s atopic status (odds ratio (95% CI)¼ 0.33(0.1–
1.12), P ¼ 0:075).
Discussion
We have previously reported associations between
GSTP1 Val105/Val105 and reduced risk of asthma,
atopy and AHR in two adult populations.10,11 In this
study, we have shown that: (i) corresponding
associations with AHR and atopy also appears to
be present in children, (ii) maternal GSTP1
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Table 4 Association of parental GSTP1Val105 allele transmission with AHRc and atopy in the child.
Transmitted maternal allele Odds ratio (95% CI)n Sig.n
Ile105 Val105
Child phenotype
AHRc
No AHRc 34 (66.7%) 17 (33.3%)
AHRc 62 (72.9%) 23 (27.1%) 0.74 (0.35–1.56) P ¼ 0:437
SPT positive
Non-atopic 25 (65.8%) 13 (34.2%)
Atopic 71 (72.5%) 27 (27.5%) 0.73 (0.33–1.62) P ¼ 0:444
IgEX100 IU/ml
Non-atopic 29 (65.9%) 15 (34.1%)
Atopic 66 (72.5%) 25 (27.5%) 0.73 (0.34–1.58) P ¼ 0:430
Atopic status
Non-atopic 16 (61.5%) 10 (38.5%)
Atopic 80 (72.7%) 30 (27.3%) 0.60 (0.25–1.44) P ¼ 0:260
Transmitted paternal allele Odds ratio (95% CI)n Sig.n
Ile105 Val105
AHRc
No AHRc 33 (64.7%) 18 (35.3%)
AHRc 58 (68.2%) 27 (31.8%) 0.85 (0.41–1.77) P ¼ 0:672
SPT positive
Non-atopic 25 (65.8%) 13 (34.2%)
Atopic 66 (67.4%) 32 (32.6%) 0.93 (0.43–2.04) P ¼ 0:862
IgEX100 IU/ml
Non-atopic 28 (63.6%) 16 (36.4%)
Atopic 62 (68.1%) 29 (31.9%) 0.82 (0.39–1.73) P ¼ 0:604
Atopic status
Non-atopic 16 (61.5%) 10 (38.5%)
Atopic 75 (68.2%) 35 (31.8%) 0.75 (0.31–1.78) P¼ 0.517
AHRc¼ corrected AHR status in child, SPT¼skin prick testing, 95% CI¼ 95% confidence interval. All data are based on 136
families in whom it was possible to ascertain allele transmission. One child did not complete IgE testing.
nAll odds ratios and P-values are based on comparisons of Val with Ile transmitted alleles.
Table 5 Relationship between parental and child genotype and parental transmission: multivariate analysis.
Child phenotype Odds ratio 95% CI Significance
AHRc
Child Val105/Val105 0.14 0.02–0.80 0.028
Maternal Val105/Val105 0.24 0.06–1.02 0.053
Paternal Val105/Val105 0.90 0.23–3.43 0.874
Maternally derived Val105 2.81 0.81–9.73 0.104
Paternally derived Val105 2.27 0.74–6.98 0.154
Atopic status (SPT positive and/or IgEX100 IU/ml)
Child Val105/Val105 0.19 0.02–1.55 0.121
Maternal Val105/Val105 0.36 0.08–1.72 0.202
Paternal Val105/Val105 0.99 0.22–4.49 0.988
Maternally derived Val105 1.92 0.41–9.05 0.409
Paternally derived Val105 1.64 0.39–6.87 0.502
Val105/Val105¼GSTP1 Val105/Val105 genotype compared with Ile105/Ile105 and Ile105/Val105 genotypes combined (Ile/Val and Ile/
Ile as the reference category). Val105¼GSTP1*Val
105 allele compared with GSTP1* Ile
105 allele (Ile as the reference category).
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genotype also is significantly associated with AHR
and atopy in the child, (iii) the effect of maternal
genotype appears independent of the child’s
genotype, (iv) paternal GSTP1 genotype had no
effect on the child’s phenotype, and (v) these
differences cannot be explained by preferential
transmission of maternal alleles to the child and
may therefore be due to the effect of maternal
genotype on the child’s intrauterine environment.
Although we have previously shown an associa-
tion in adults with atopic and occupational asthma,
this is the first study to explore the relationship
between AHR, atopy and GSTP1 genotype in
children. The results for AHR and atopy are similar
to, if slightly weaker than, those we reported in
adults.10,11 This study shows a three-fold reduction
in risk in both AHR and atopy in association with the
Val105/Val105 genotype in children. This compares
with five-, four- and 10-fold reductions in risk of
AHR, SPT positivity and IgEX100 IU/ml reported in
adults.10 The relationship between GSTP1, a gene
that is believed to influence the response to
oxidative stress, and asthma, an inflammatory
disease of the airways, can be explained by the
central role of oxidative stress in airway inflamma-
tion in adults and children.27,28 The mechanism by
which the enzyme may influence atopy is less clear.
Since the products of oxidative stress (e.g. lipid
hydroperoxides) promote arachidonic acid mobili-
sation and eicosanoid synthesis,29 GSTP1 may also
influence the synthesis of eicosanoids by modulat-
ing levels of these products.2 This pro-inflammatory
cascade leads to the release of mediators and
stimulation of Th2 lymphocytes resulting in activa-
tion of mast cells, B-cells and eosinophils with
increased release of histamine and production of
IgE. Furthermore, eicosanoids are substrates for
GSTP1,2 suggesting a more direct role in the
synthesis of these mediators.
This preliminary study also shows that AHRc and,
to a lesser extent, atopy in children appears to be
influenced by maternal but not paternal genotype.
We found no evidence that this is due to prefer-
ential transmission of maternal GSTP1 alleles to the
child. It is possible, therefore, that the greater
maternal effect is due to the effects that the
maternal genotype exerts on the child’s intrauter-
ine environment. GSTP1 polymorphisms have been
shown to influence GSTP1 activity13–16 and there-
fore the ability to detoxify exogenous toxins and
the products of oxidative stress. It is possible that
mothers with a reduced ability to detoxify exogen-
ous pollutants expose their foetus to more toxins
resulting in damage to the developing lung. For
example, exposure of the foetus to cigarette smoke
is associated with decreased airway growth, re-
duced maximal expiratory flow at functional
residual capacity (VmaxFRC) at birth and an in-
creased risk of wheeze and asthma in childhood.1
The GSTP1 enzyme can utilise various potentially
toxic chemicals present in cigarette smoke such as
PAH and acrolein.2 Children whose mothers have
impaired/less effective GSTP1-1 function may
therefore be at increased risk of the effects of
maternal smoking during pregnancy, including
wheeze and asthma. They may also be at risk from
a wide variety of other environmental toxins. It was
not possible to explore this hypothesis further in
this study as only 15 mothers admitted smoking
during pregnancy and data on other environmental
exposures were not available. In a secondary
analysis, we examined associations between pro-
band and parental genotype on lung function (FEV1,
FVC, FEF25–75, FEV1/FVC) in the child. No significant
associations were identified (data not shown),
although this may reflect the importance of genes
involved in airway remodelling, rather than those
responsible for detoxification or protection against
oxidative stress.
The results of the TDT analyses confirm the
expected lack of association between maternal and
paternal transmitted alleles and risk in the child.
However, given that the case-control analysis
showed a significant association between GSTP1
genotype in the child and risk of both atopy and
AHRc, it may have been expected that the TDT
association with transmitted versus non-trans-
mitted Val105 alleles would be significant. The
reasons for the lack of significance may be either
due to small numbers of trios, or due to the
confounding effect of the association between
maternal genotype and risk in the child.
Oxidative stress has pleiotrophic effects in the
lung. In addition to the role of oxidants in airway
epithelial cell injury, there is evidence that
intracellular redox is important in determining
the balance between Th1- and Th2-mediated
immunity.30,31 Redox potential is regulated by the
intracellular ratio of oxidised to reduced glu-
tathione (GSSG:GSH ratio) and several studies have
identified a relationship between this ratio and
cytokine expression in different lung cells.31–33 GSH
depletion is linked with increased expression of
cytokines associated with a pro-inflammatory state
(e.g. TNFa; IL-12).31–33 Furthermore, the GSSG:GSH
ratio is increased by Th1 (interferon-g) and
decreased by Th2-associtated (IL-4) cytokines.
32
Studies in mice have shown that levels of GSH in
antigen-presenting cells have a direct effect on the
Th1/Th2 cytokine response pattern with GSH
depletion inhibiting Th1-associated cytokine
production and favouring Th2-responses.
31 We
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speculate therefore, that the level of expression of
glutathione-metabolising enzymes, such as GSTP1,
may be associated with a persistence of Th2-
mediated immunity resulting in asthma, atopy and
allergic disease in childhood. This is supported by
studies showing firstly, that expression of GSTP1 is
regulated by redox status34 and secondly, the
transition from Th2–Th1 immunity in childhood
may be influenced by events in early pregnancy
when expression of GSTP1-1 in foetal lung is high
relative to that in adults.12
This study includes relatively small numbers of
children who do not have AHR or atopy which may
explain the slightly unusual relationship between
maternal, paternal and child atopy. Rather than
maternal atopy predominating, similar numbers of
mothers (83%) and fathers (84%) of atopic children
were themselves atopic. The associations between
AHRc and atopy and the child’s GSTP1 genotype
are, however, consistent in the study and compare
well with those reported in adults.10,11 SPT and IgE
may measure different phenotypic characteristics
and combining them to define an overall ‘atopy
phenotype’ can be criticised. This approach has,
however, been used in many other studies and, to
avoid confusion in this study, the results of SPT and
IgE measurement are also presented individually. It
is possible that the identified associations with
AHRc may be influenced by the inclusion of atopy in
the correction models. To explore this, we also
assessed associations between GSTP1 and AHR
corrected for the child’s age, gender, height, and
baseline FEV1, FVC, FEV1/FVC and FEF25–75, but not
atopic status. Similar results were obtained for
maternal AHRc (PC20c, P ¼ 0:071; DRSc, P ¼ 0:026)
and paternal AHRc (PC20c, P ¼ 0:562; DRSc,
P ¼ 0:407), although the association between AHRc
and GSTP1 genotype in the child was lost (PC20c,
P ¼ 0:441; DRSc, P ¼ 0:115).
The analysis exploring synergy between maternal
and child Val105/Val105 genotype was based on only
9 maternal-child pairs and it is possible that the
apparent lack of association between parental
transmission of GSTP1 alleles to the child was also
due to small numbers. However, post hoc power
calculations, based on maternal allele transmission
and the affected: unaffected ratios observed,
suggested that 133 and 167 probands were needed
to identify associations (odds ratios of p0.25 as
identified in previous studies) between maternal
GSTP1 genotype and AHRc and atopy in the child
with 80% power and 95% significance. These sample
sizes compared well with the 145 probands studied.
However, due to the small number of subjects in
some groups, these data should be treated with
caution until confirmation in further groups is
performed. This is particularly true for the mater-
nal genotype effect since this is the first study to
identify this association. In the context of the
effect of the child’s GSTP1 genotype on risk,
although the magnitude of the effect observed in
children is smaller than that seen in adults, the fact
that the association has been confirmed in three
independent populations adds weight to these
observations. Indeed, as such this association fulfils
many of the essential requirements absent in most
case-control studies.35
In summary, this study confirms that GSTP1
genotype in both children and their mothers is
associated with a reduced risk of atopy and AHR in
schoolchildren. The effect of maternal genotype
appears independent of the child’s genotype and
not due to preferential transmission of maternal
alleles to the child. Maternal GSTP1 genotype may
influence atopy and AHR in the child by altering the
child’s intrauterine environment.
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